Edition:
United States

Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

32.83USD
26 May 2017
Change (% chg)

$-0.45 (-1.35%)
Prev Close
$33.28
Open
$33.33
Day's High
$34.23
Day's Low
$32.63
Volume
137,101
Avg. Vol
420,330
52-wk High
$48.20
52-wk Low
$9.40

Latest Key Developments (Source: Significant Developments)

Esperion reports Q1 net loss per common share $1.80
Thursday, 4 May 2017 04:05pm EDT 

May 4 (Reuters) - Esperion Therapeutics Inc :Esperion provides Bempedoic Acid development program updates; reports first quarter 2017 financial results.Esperion Therapeutics Inc - esperion expects full-year 2017 net cash used in operating activities to be approximately $125 to $135 million.Qtrly net loss per common share $1.80.  Full Article

Boxer Capital reports 5.3 pct passive stake in Esperion Therapeutics
Thursday, 23 Mar 2017 04:32pm EDT 

Esperion Therapeutics Inc : Boxer Capital LLC reports 5.3 percent passive stake in Esperion Therapeutics Inc as of March 20 - SEC filing Source: (http://bit.ly/2mZu8Mb) Further company coverage: [ESPR.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Esperion announces FDA confirmation to approval for an LDL-C lowering indication for bempedoic acid
Monday, 20 Mar 2017 07:30am EDT 

Esperion Therapeutics Inc : Esperion announces fda confirmation regarding regulatory pathway to approval for an ldl-c lowering indication for bempedoic acid . Esperion therapeutics inc - on track to submit nda for an ldl-c lowering indication by 1h 2019 . Esperion therapeutics- remain focused on completing global pivotal phase 3 program for bempedoic acid . Esperion therapeutics inc - remain focused on reporting top-line results from our long-term safety and tolerability study by q2 2018 .Esperion therapeutics- expects to submit nda for cardiovascular disease risk reduction indication to fda, marketing authorization application to ema by 2022.  Full Article

Esperion posts Q4 loss per share $1.29
Wednesday, 22 Feb 2017 07:30am EST 

Esperion Therapeutics Inc : Esperion provides bempedoic acid development program update; reports fourth quarter and full year 2016 financial results . Esperion Therapeutics Inc - expects full-year 2017 net cash used in operating activities to be approximately $125 to $135 million . Esperion Therapeutics Inc says estimates that current cash resources are sufficient to fund operations into early 2019 . Qtrly loss per share $1.29 .Esperion Therapeutics Inc - company estimates that current cash resources are sufficient to fund operations into early 2019.  Full Article

Esperion Therapeutics reports qtrly loss per share $0.77
Thursday, 3 Nov 2016 04:05pm EDT 

Esperion Therapeutics Inc : Esperion Therapeutics Inc says expects full-year net cash used in operating activities in 2016 will be approximately $65 million . Esperion Therapeutics Inc - qtrly loss per share $0.77 . Q3 earnings per share view $-0.82 -- Thomson Reuters I/B/E/S .Esperion Therapeutics provides bempedoic acid development program updates; reports third quarter 2016 financial results.  Full Article

BB Biotech reports 5.1 pct passive stake in Esperion Therapeutics
Tuesday, 27 Sep 2016 04:22pm EDT 

Esperion Therapeutics Inc :BB Biotech AG reports 5.1 pct passive stake in Esperion Therapeutics as of September 22, 2016 - SEC filing.  Full Article

Esperion Therapeutics reports Q2 net loss of $14 mln
Thursday, 4 Aug 2016 04:05pm EDT 

Esperion Therapeutics Inc : Estimates current cash resources are sufficient to fund operations into 2019 . Esperion Therapeutics provides bempedoic acid development program updates; reports second quarter 2016 financial results . Esperion had a net loss of $14.0 million for q2 of 2016 compared to $12.4 million .Esperion expects full-year 2016 net cash used in operating activities in 2016 will be approximately $65 to $75 million.  Full Article

Esperion Therapeutics provides regulatory update for Bempedoic Acid
Tuesday, 28 Jun 2016 04:05pm EDT 

Esperion Therapeutics Inc : Esperion Therapeutics Inc says intends to initiate planned CVOT in statin intolerant patients who are at high risk for CV disease in Q4 of 2016 . Esperion expects full-year 2016 net cash used in operating activities to be between $65 to $75 million . Expects full-year 2016 cash and cash equivalents and investment securities to be approximately $220 million at December 31, 2016 . Current cash resources are expected to be sufficient to fund operations into early 2019 .Esperion Therapeutics provides clinical development and regulatory update for bempedoic acid.  Full Article

Esperion Therapeutics announces initiation of phase 2 Clinical Study of Bempedoic Acid in Patients Treated With High-Dose Statin Therapy
Tuesday, 12 Jan 2016 04:05pm EST 

Esperion Therapeutics Inc:Announced initiation of its Phase 2 pharmacokinetics/pharmacodynamics (PK/PD) study (ETC-1002-035) of bempedoic acid in patients treated with atorvastatin 80 mg, the most commonly prescribed high-dose statin.Expects to announce top-line results from the study by mid-year.  Full Article

Esperion Therapeutics announces positive top-line phase 2 results for etc-1002 in patients with hypercholesterolemia and hypertension
Tuesday, 28 Jul 2015 07:30am EDT 

Esperion Therapeutics Inc:Announces positive top-line phase 2 results for etc-1002 in patients with hypercholesterolemia and hypertension.Says the ldl-cholesterol lowering effect of ETC-1002 was statistically significant.Etc-1002 produced neutral effect on blood pressure, appeared safe and well-tolerated, produced no muscle-related adverse events.Says ETC-1002 appeared to be safe and well-tolerated and produced no muscle-related adverse events.  Full Article

More From Around the Web

BRIEF-Esperion reports Q1 net loss per common share $1.80

* Esperion provides Bempedoic Acid development program updates; reports first quarter 2017 financial results